Syndax Q3 revenue rises 82% on Revuforj and post-transplant demand
Syndax Pharmaceuticals reported Q3 revenue up 82% year on year to $83.3 million, driven by Revuforj and Niktimvo, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Syndax Pharmaceuticals posted third-quarter revenue up 82% year on year, reaching $83.3 million. Most of the gain came from its Revuforj and Niktimvo products.
Management expects the resumption of treatment after transplant to add further momentum to Revuforj sales. At the same time, the company is advancing trials in frontline treatment and developing new programs in its pipeline.
why it matters
Earnings from a company of this size matter for the biotech sector, because growth in sales of already marketed drugs shows how fast the commercial business is expanding. Investors typically compare such figures with market expectations and with plans for new programs, which this report describes only briefly.
market impact
Shares of SNDX: strong revenue growth supports interest in the stock after the report
tags
instruments
sources
- SNDX: Q3 revenue grew 82% as Revuforj demand and post-transplant momentum strengthened — TradingView, 2 November 2026 at 23:57 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗